All
Priority Review Granted to Lenvatinib for RAI-Refractory DTC
October 18th 2014The FDA has granted a priority review to the oral multiple tyrosine kinase receptor inhibitor lenvatinib as a treatment for patients with progressive, radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC).
Novel Combination May Extend Survival in Ovarian Cancer
October 17th 2014Two agents with contrasting mechanisms of actions exert synergistic effects while limiting tumor blood supply in ovarian cancer. Patient enrollment began this month (October 2014) for a new phase 1b/2 clinical study1 to evaluate this novel combination with the VDA fosbretabulin plus pazopanib.
Bayer Suspends Production of Radium-223 Due to Manufacturing Problem
October 16th 2014Production of the prostate cancer drug radium-223 (Xofigo) has been suspended indefinitely by its maker, Bayer HealthCare Pharmaceuticals, due to a manufacturing problem. The company confirmed the manufacturing suspension in a statement released to Targeted Oncology.
Q & A With Emmanuel S. Antonarakis, MBBCh: AR-V7 and Resistance to AR-Targeting Agents
October 7th 2014To gain further insight into AR-V7 and resistance to AR-targeting agents, Targeted Oncology interviewed the lead author, Emmanuel S. Antonarakis, MBBCh, an assistant professor at Johns Hopkins Medicine.
Nivolumab Combinations to be Explored in NSCLC
October 7th 2014Several clinical trials combining nivolumab (Opdivo) with targeted therapies against ALK, c-MET, and T790M for patients with non-small cell lung cancer (NSCLC) have been established as part of a collaboration between Novartis and Bristol-Myers Squibb (BMS).
Bristol-Myers Squibb Files Suit Over Merck's Pembrolizumab
September 11th 2014Bristol-Myers Squibb has filed a lawsuit over Merck’s newly approved immunotherapy drug pembrolizumab, contending that the much-heralded PD-1 inhibitor will infringe upon patents that Bristol-Myers holds on the groundbreaking technology.
New Insights From ENCODE Datasets, NIH Issues Finalized Genomic Data Sharing Policy
September 2nd 2014A series of papers have been published in the journal Nature in which researchers conducted detailed comparisons of the worm, fly, and human genomes using data from the ENCODE and modENCODE projects.
Eltrombopag for Severe Aplastic Anemia Approved by FDA
August 27th 2014The FDA has approved eltrombopag (Promacta) as a treatment for patients with severe aplastic anemia (SAA) following an insufficient response to immunosuppressive therapy, based on data from an open-label, single-arm phase II trial.